Halozyme Therapeutics Net Long-Term Debt 2010-2025 | HALO

Halozyme Therapeutics net long-term debt for the twelve months ending March 31, 2025 was $-0.003B, a 91.89% decline year-over-year.

  • Halozyme Therapeutics annual net long-term debt for 2024 was $0B, a 100% decline from 2023.
  • Halozyme Therapeutics annual net long-term debt for 2023 was $-0.013B, a 102.43% decline from 2022.
  • Halozyme Therapeutics annual net long-term debt for 2022 was $0.555B, a 33.58% increase from 2021.

Halozyme Therapeutics Net Long-Term Debt 2010-2025 | HALO

  • Halozyme Therapeutics annual net long-term debt for 2024 was $0B, a 100% decline from 2023.
  • Halozyme Therapeutics annual net long-term debt for 2023 was $-0.013B, a 102.43% decline from 2022.
  • Halozyme Therapeutics annual net long-term debt for 2022 was $0.555B, a 33.58% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$226.4B
Amgen (AMGN)$166.3B
Gilead Sciences (GILD)$141.3B
Vertex Pharmaceuticals (VRTX)$122.5B
Bristol Myers Squibb (BMY)$99.7B
CSL (CSLLY)$85.2B
GSK (GSK)$77.9B
Regeneron Pharmaceuticals (REGN)$61.8B
Alnylam Pharmaceuticals (ALNY)$42.5B
Argenex SE (ARGX)$35.2B
BioNTech SE (BNTX)$27.5B
Royalty Pharma (RPRX)$20.2B
Insmed (INSM)$19.6B
Biogen (BIIB)$19.2B
Illumina (ILMN)$16.6B
Genmab (GNMSF)$14.9B
Genmab (GMAB)$14.7B
Incyte (INCY)$13.7B
Moderna (MRNA)$13.4B
Exelixis (EXEL)$12.4B
BioMarin Pharmaceutical (BMRN)$11.4B
QIAGEN (QGEN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.4B
Exact Sciences (EXAS)$9.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.7B
Blueprint Medicines (BPMC)$8.3B
Legend Biotech (LEGN)$8.1B
Roivant Sciences (ROIV)$7.7B